[1] Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers, 2018; 4, 18026. doi:  10.1038/nrdp.2018.26
[2] Boroujeni ZB, Shamsaei S, Yarahmadi M, et al. Distribution of invasive fungal infections: molecular epidemiology, etiology, clinical conditions, diagnosis and risk factors: a 3-year experience with 490 patients under intensive care. Microb Pathog, 2021; 152, 104616. doi:  10.1016/j.micpath.2020.104616
[3] Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev, 2007; 20, 133−63. doi:  10.1128/CMR.00029-06
[4] Guo FM, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. J Antimicrob Chemother, 2013; 68, 1660−8. doi:  10.1093/jac/dkt083
[5] Wisplinghoff H, Ebbers J, Geurtz L, et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents, 2014; 43, 78−81. doi:  10.1016/j.ijantimicag.2013.09.005
[6] Rodrigues LS, Motta FA, Picharski GL, et al. Invasive candidiasis: risk factor for mortality in a pediatric tertiary care hospital in south of Brazil. Medicine, 2019; 98, e15933. doi:  10.1097/MD.0000000000015933
[7] Zeng ZR, Tian G, Ding YH, et al. Epidemiology, antifungal susceptibility, risk factors and mortality of invasive candidiasis in neonates and children in a tertiary teaching hospital in Southwest China. Mycoses, 2020; 63, 1164−74. doi:  10.1111/myc.13146
[8] Wang L, Tong ZH, Wang Z, et al. Single-center retrospective study of the incidence of, and risk factors for, non-C. albicans invasive candidiasis in hospitalized patients in China. Med Mycol, 2014; 52, 115−22.
[9] Yang ZT, Wu L, Liu XY, et al. Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in Shanghai. BMC Infect Dis, 2014; 14, 241. doi:  10.1186/1471-2334-14-241
[10] Tortorano AM, Prigitano A, Lazzarini C, et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection, 2013; 41, 655−62. doi:  10.1007/s15010-013-0455-6
[11] Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis, 2012; 54, 1739−46. doi:  10.1093/cid/cis305
[12] Liu W, Tan JW, Sun JM, et al. Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study. J Antimicrob Chemother, 2014; 69, 162−7. doi:  10.1093/jac/dkt330
[13] Tan BH, Chakrabarti A, Li RY, et al. Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. Clin Microbiol Infect, 2015; 21, 946−53. doi:  10.1016/j.cmi.2015.06.010
[14] Li Y, Du MM, Chen LA, et al. Nosocomial bloodstream infection due to Candida spp. in China: species distribution, clinical features, and outcomes. Mycopathologia, 2016; 181, 485−95. doi:  10.1007/s11046-016-9997-3
[15] Wang H, Xu YC, Hsueh PR. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region. Future Microbiol, 2016; 11, 1461−77. doi:  10.2217/fmb-2016-0099
[16] Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis, 2019; 71, 1367−76.
[17] Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med, 2014; 40, 1429−48. doi:  10.1007/s00134-014-3355-z
[18] León C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med, 2006; 34, 730−7. doi:  10.1097/01.CCM.0000202208.37364.7D
[19] Leroy G, Lambiotte F, Thévenin D, et al. Evaluation of "Candida score" in critically ill patients: a prospective, multicenter, observational, cohort study. Ann Intensive Care, 2011; 1, 50. doi:  10.1186/2110-5820-1-50
[20] Song YG, Chen XL, Yan Y, et al. Prevalence and antifungal susceptibility of pathogenic yeasts in China: a 10-year retrospective study in a teaching hospital. Front Microbiol, 2020; 11, 1401. doi:  10.3389/fmicb.2020.01401
[21] StataCorp. Stata statistical software: release 15. College Station, TX: StataCorp LLC. 2017.
[22] Chiang CH, Pan SC, Yang TS, et al. Healthcare-associated infections in intensive care units in Taiwan, South Korea, and Japan: recent trends based on national surveillance reports. Antimicrob Resist Infect Control, 2018; 7, 129. doi:  10.1186/s13756-018-0422-1
[23] Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag, 2014; 2014, 95−105.
[24] Kett DH, Azoulay E, Echeverria PM, et al. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med, 2011; 39, 665−70. doi:  10.1097/CCM.0b013e318206c1ca
[25] Pfaller MA, Messer SA, Moet GJ, et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents, 2011; 38, 65−9. doi:  10.1016/j.ijantimicag.2011.02.016
[26] Xiao M, Sun ZY, Kang M, et al. Five-year national surveillance of invasive candidiasis: species distribution and azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study. J Clin Microbiol, 2018; 56, e00577−18.
[27] Hsu JF, Lai MY, Lee CW, et al. Comparison of the incidence, clinical features and outcomes of invasive candidiasis in children and neonates. BMC Infect Dis, 2018; 18, 194. doi:  10.1186/s12879-018-3100-2
[28] Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis, 2009; 48, 1695−703. doi:  10.1086/599039
[29] Lau AF, Kabir M, Chen SCA, et al. Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol. J Clin Microbiol, 2015; 53, 1324−30. doi:  10.1128/JCM.03239-14
[30] Dubau B, Triboulet C, Winnock S. Use of the colonization index. Ann Fr Anesth Reanim, 2001; 20, 418−20. doi:  10.1016/S0750-7658(01)00375-6
[31] Cohen JF, Ouziel A, Matczak S, et al. Diagnostic accuracy of serum (1, 3)-beta-D-glucan for neonatal invasive candidiasis: systematic review and meta-analysis. Clin Microbiol Infect, 2020; 26, 291−8. doi:  10.1016/j.cmi.2019.09.010
[32] Lo Cascio G, Koncan R, Stringari G, et al. Interference of confounding factors on the use of (1, 3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit. Eur J Clin Microbiol Infect Dis, 2015; 34, 357−65. doi:  10.1007/s10096-014-2239-z
[33] Li FT, Yu XT, Ye LY, et al. Clinical value of (1, 3)-β-D-glucan, mannan, antimannan IgG and IgM antibodies in diagnosis of invasive candidiasis. Med Mycol, 2019; 57, 976−86. doi:  10.1093/mmy/myy158
[34] Ampel NM. Serum 1, 3-β-D-Glucan levels predict intra-abdominal candidiasis. NEJM J Watch, 2013.
[35] De Pascale G, Posteraro B, D'Arrigo S, et al. (1, 3)-β-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial. Crit Care, 2020; 24, 550. doi:  10.1186/s13054-020-03265-y
[36] Jaijakul S, Vazquez JA, Swanson RN, et al. (1, 3)-β-D-Glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis, 2012; 55, 521−6. doi:  10.1093/cid/cis456
[37] Guo JF, Wu YB, Lai WM, et al. The diagnostic value of (1, 3)-β-D-glucan alone or combined with traditional inflammatory markers in neonatal invasive candidiasis. BMC Infect Dis, 2019; 19, 716. doi:  10.1186/s12879-019-4364-x
[38] Castanheira M, Messer SA, Rhomberg PR, et al. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). Diagn Microbiol Infect Dis, 2016; 85, 200−4. doi:  10.1016/j.diagmicrobio.2016.02.009
[39] Chi HW, Yang YS, Shang ST, et al. Candida albicans versus non-albicans bloodstream infections: the comparison of risk factors and outcome. J Microbiol Immunol Infect, 2011; 44, 369−75. doi:  10.1016/j.jmii.2010.08.010
[40] Pappas PG, Kauffman CA, Andes DR, et al. Executive Summary: clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis, 2016; 62, 409−17. doi:  10.1093/cid/civ1194